Lilly jumps on animal health IPO and quarterly figures

24 July 2018

Eli Lilly (NYSE: LLY) gained 2% in market value in an hour’s trading on Tuesday following news that it plans an initial public offering (IPO) for its Elanco Animal Health unit, and the presentation of the US drugmaker’s latest financial results.

The company has completed its strategic reviewed of the unit and announced that it will file a registration statement in the coming weeks with the US Securities and Exchange Commission for a potential IPO of a minority ownership stake in Elanco as a separate company.

This offering is expected to represent an ownership stake of less than 20% and the IPO process should take place later in 2018.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK